A Phase II, Double-Blind, Placebo-Controlled, Multi-Centre, Randomised Study of ZD4054 Plus Carboplatin and Paclitaxel or Placebo Plus Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer Sensitive to Platinum-Based Chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 27 Apr 2013
At a glance
- Drugs Zibotentan (Primary) ; Carboplatin; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 06 Aug 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 05 Jun 2012 Actual patient number is 120 according to ClinicalTrials.gov.
- 05 Aug 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History